Dysport for Glabellar Lines: What Patients Should Know About Results, Timing, and Safety

If you want broader context on injectable options without product comparisons, see the Injectables overview page.

What Dysport Is and How It Works

Dysport is the brand name for abobotulinumtoxinA, a prescription botulinum toxin product given by injection. The U.S. Food and Drug Administration approves Dysport for the temporary improvement in the appearance of moderate to severe glabellar lines in adults under 65 years of age, as stated in the FDA-approved Dysport label. Glabellar lines refer to the vertical “11” lines that form between the eyebrows when facial muscles contract. The official prescribing information outlines the product’s clinical testing, safety profile, and duration expectations.

Botulinum toxin type A products reduce muscle activity by interfering with the nerve signals that trigger muscle contraction, and NIH News in Health describes this effect in patient-facing language. CDC clinical guidance also describes botulinum neurotoxins as impairing acetylcholine release at nerve endings in its MMWR botulism guidelines. When the targeted muscles relax, the overlying skin appears smoother during facial expression. This effect does not add volume or change skin texture directly.

Dysport addresses dynamic wrinkles that form from repeated muscle movement rather than static lines caused by skin thinning or volume loss. MedlinePlus notes that botulinum toxin comes from bacteria and clinicians use small doses medically, as summarized in its botulinum toxin overview. The FDA label also describes Dysport as an acetylcholine release inhibitor and a neuromuscular blocking agent in its indications and usage section of the prescribing information. Each of these sources supports the same core point: the treatment targets muscle-driven movement patterns, which shapes what it can and cannot change.

Patients sometimes assume “stronger effect” means “more frozen,” yet the goal in many cosmetic plans is controlled softening rather than total immobility. Clinical studies use standardized rating scales and defined time points to measure improvement, which keeps expectations tied to what researchers actually tracked in trials. A practical way to think about Dysport involves how much the frown muscle intensity changes during normal expression, not how the skin looks under harsh lighting. That distinction matters because glabellar lines can remain faintly visible at rest even when expression-driven creasing decreases.

What Dysport Is Approved to Treat

The FDA indication for aesthetic use in the United States focuses specifically on moderate to severe glabellar lines. Clinical trials measured improvement using standardized grading scales that assessed wrinkle severity at rest and during frown. Investigators evaluated outcomes at defined time points, with Day 30 serving as a primary endpoint in pivotal studies. Treatment success required both a rating of “none” or “mild” and at least a two-grade improvement from baseline.

Across pivotal placebo-controlled trials summarized in the U.S. label, approximately 52% to 60% of treated patients met the composite success criteria at Day 30, compared with 0% of placebo-treated participants, as shown in the clinical study tables in the FDA-approved Dysport label. These results reflect measurable improvement under controlled study conditions rather than informal visual impressions. Dysport reduces the severity of glabellar lines for up to four months, according to the prescribing information. Individual experience can vary, yet the label sets realistic boundaries for expected duration.

The “under 65” language can surprise patients, yet it reflects how the FDA-reviewed cosmetic studies defined their participant groups and labeling scope in the U.S. prescribing information. That detail does not imply older patients cannot benefit in real-world care, but it does mean patients should anchor expectations to what the label directly studied. A careful consultation also helps separate glabellar-line goals from other concerns, such as forehead lines, crow’s feet, or skin texture changes. Those topics can matter clinically, yet this page stays focused on the FDA-indicated glabellar area.

Timeline: When Results Start and How Long They Last

Patients often ask when they will see changes after injection. Peer-reviewed literature reviewing abobotulinumtoxinA use in the upper face reports that some individuals notice effects within 48 to 72 hours, as summarized in a systematic literature review on onset and duration. Studies also describe continued improvement over the first week, with peak changes frequently assessed around Day 7 in certain trial designs. Clinical endpoints in the FDA label center on Day 30, which provides a standardized benchmark for comparison.

Duration expectations should remain grounded in label-supported data. The prescribing information states that Dysport reduces the severity of glabellar lines for up to four months in the FDA-approved label. Dermatology patient education also commonly frames botulinum toxin results as lasting about three to four months, as described in the American Academy of Dermatology overview. Real-world variation depends on individual muscle strength, metabolism, and treatment plan, yet no source in the current evidence base supports permanent change from a single treatment.

Timing also influences how people judge the outcome. A university dermatology program notes that effects can begin soon after injection, though maximal change may take about two weeks, as explained by UTHealth Houston Dermatology. A patient who checks results daily in a magnifying mirror can feel uncertain in the early days. A more practical approach focuses on the full first two weeks, then evaluates whether the frown line intensity feels meaningfully reduced during normal expression.

Retreatment timing should follow safety guidance and clinical judgment rather than “chasing” a moving target week to week. The label frames effect as temporary, which supports a maintenance rhythm instead of a one-time expectation, as emphasized in the FDA-approved prescribing information. Many patients find that documenting a neutral-expression photo at baseline and again at about two weeks creates a calmer, more accurate comparison than repeated close-up checks. That habit also makes follow-up discussions more concrete for both patient and clinician.

Safety Overview: What the Label Emphasizes

Every botulinum toxin product approved in the United States carries a boxed warning. The warning explains that effects may spread beyond the injection site and produce symptoms consistent with botulinum toxin exposure, as stated in the FDA-approved Dysport label. Reported symptoms include difficulty swallowing, speaking, or breathing, and these can occur hours to weeks after injection. Swallowing or breathing complications can become life-threatening, so urgent medical attention is necessary if such symptoms arise.

Patients often hear safety terms quickly during scheduling or consent, then forget the details later. This quick-reference table translates label and clinical terms into plain language so you can recognize what matters and what action fits the situation.

Label / clinical term	What it means in plain language	Why it matters to patients	What to do (patient action)
Glabellar lines	The vertical “11” lines between the eyebrows that deepen when you frown.	This is the specific FDA-approved cosmetic target for Dysport in the U.S.	Confirm your main concern matches this area and describe what you see at rest versus during expression.
“Temporary improvement”	A time-limited reduction in how strong the frown lines look, not a permanent change.	It frames realistic expectations for results and retreatment planning.	Plan around a temporary effect and schedule follow-up based on how long your result lasts.
Boxed warning: distant spread of toxin effect	In rare cases, effects may extend beyond the injection area and cause botulinum-toxin–like symptoms.	The label stresses that swallowing or breathing problems can be serious and need urgent attention.	Seek urgent medical evaluation if you develop swallowing, speaking, or breathing difficulty hours to weeks after treatment.
Eyelid ptosis	A temporary droop of the upper eyelid reported in cosmetic trials.	It can affect appearance and, in some cases, vision comfort.	Contact the clinic if you notice eyelid droop; ask what monitoring and follow-up they recommend for your case.
Eyelid edema	Swelling around the eyelid area reported in studies.	It can look alarming even when it resolves without long-term issues.	Report swelling that concerns you, especially if it comes with pain, vision changes, or allergy symptoms.
Dry eye / reduced blinking	The label notes reduced tear production or blinking can occur after glabellar-line treatment.	Dry eye can become more than “minor dryness” in people prone to irritation or corneal problems.	Tell your clinician about prior dry eye, eye surgery, or contact lens use; seek evaluation for persistent pain or vision changes.
Hypersensitivity reaction	A serious allergic-type reaction that has been reported with Dysport.	The label describes potentially severe outcomes, including anaphylaxis.	Disclose prior reactions to botulinum toxin products; seek urgent care for rapid swelling, hives, or breathing symptoms.
Contraindication: infection at injection site	Active infection where the injections would be placed.	The label lists this as a “do not treat” situation.	Reschedule if you have an infection, inflamed lesion, or significant skin irritation in the planned area.
Units are not interchangeable	Dysport dosing units do not convert to other botulinum toxin products.	Unit counts cannot compare “strength,” “value,” or expected duration across brands.	Ask about expected outcome and safety plan rather than comparing unit numbers between products.
Medication interaction: aminoglycosides / neuromuscular transmission agents	Certain antibiotics and related agents can amplify muscle-weakness effects.	The label flags increased effect risk when used together.	Bring a current medication list and disclose recent antibiotics so timing and precautions can be reviewed.

Placebo-controlled cosmetic trials for glabellar lines reported several common adverse reactions at rates of 2% or higher, as listed in the FDA-approved Dysport label. These included headache, injection site pain or reaction, eyelid edema, eyelid ptosis, upper respiratory tract infection, nasopharyngitis, sinusitis, nausea, and blood present in urine. Eyelid ptosis refers to drooping of the upper eyelid, which can temporarily affect eye appearance and function. Most reported reactions in trials were mild to moderate in severity, though each patient should discuss personal risk factors with a clinician.

Dry eye and corneal exposure represent additional concerns in glabellar-line treatment. The label notes reduced blinking and tear production as potential effects, and it advises that persistent symptoms may warrant ophthalmology referral in the prescribing information. Patients with prior eye conditions or contact lens use may require closer observation. Symptoms such as persistent eye pain, visual changes, or a sensation of dryness should prompt medical evaluation.

Safety discussions feel clearer when patients separate common, short-lived issues from rare, urgent symptoms. Headache or local tenderness can happen after many injections, while swallowing or breathing difficulty carries a different level of concern in the boxed warning language. A good consent discussion should also explain why clinicians ask about neuromuscular conditions, recent antibiotics, and prior reactions. Those questions connect directly to the label’s warnings and interaction cautions, not to generic paperwork.

Who Should Not Receive Dysport

Dysport is contraindicated in individuals with known hypersensitivity to any botulinum toxin product or to any of its components, as listed under contraindications in the FDA-approved label. The prescribing information notes that the formulation may contain trace amounts of cow’s milk protein. A history of serious allergic reaction to botulinum toxin products should preclude treatment unless a specialist determines otherwise. Infection at the proposed injection site also represents a clear contraindication.

Certain neuromuscular disorders increase the risk of clinically significant swallowing or breathing difficulties after botulinum toxin exposure, as described in warnings and precautions in the Dysport prescribing information. Patients with a history of conditions affecting muscle or nerve function should disclose that information before treatment. Individuals who have experienced swallowing or breathing problems in the past require individualized risk assessment. A transparent medical history supports safer decision-making.

Patients often ask whether they should postpone treatment during an acute illness, and the safest answer depends on context and clinician guidance rather than a single universal rule. The label’s contraindication language clearly includes infection at the injection site, yet overall timing decisions also consider how a patient feels and what medications they may need, as outlined in the Warnings and Precautions and Drug Interactions sections. A straightforward way to reduce risk involves sharing recent antibiotic use, new neurologic symptoms, and any prior unusual response to a toxin product. That level of detail helps clinicians match the plan to the label’s safety framework.

Medication and Interaction Considerations

The prescribing information highlights potential interactions with aminoglycoside antibiotics and other agents that interfere with neuromuscular transmission in the drug interactions section of the FDA label. Concomitant use of such medications may increase the effect of the toxin and amplify muscle weakness. Anticholinergic drugs may also enhance certain systemic effects when used together with Dysport. A complete medication list, including supplements and recent antibiotic use, helps clinicians evaluate risk appropriately.

Units of Dysport are not interchangeable with units of other botulinum toxin products, as emphasized in warnings and precautions in the FDA-approved prescribing information. The label clearly states that dosing units cannot convert from one product to another. Patients should not compare unit numbers across brands as a measure of strength or value. Safe and appropriate dosing depends on product-specific clinical data and physician judgment.

Patients can make the interaction discussion easier by organizing information in the same way clinicians think about it. A current medication list should include prescription drugs, over-the-counter products, supplements, and any antibiotics taken recently, since the label calls out agents that may affect neuromuscular transmission in the Drug Interactions section. Sharing past cosmetic toxin history also matters, including when the last treatment occurred and whether results felt uneven or unusually strong. Those details help clinicians avoid assumptions that “more units” equals “better,” which the label explicitly warns against when it states units are not interchangeable.

Setting Realistic Expectations

Dysport addresses dynamic glabellar lines, not all visible signs of facial aging. Patients who expect complete elimination of every line at rest may experience disappointment. Clinical trial endpoints focused on improvement in severity rather than total absence of lines in every lighting condition. Realistic goals center on softening frown lines and reducing the intensity of expression-related creasing.

Timing also shapes satisfaction. Changes can begin within days, yet peak visible improvement often unfolds over the first one to two weeks, a pattern discussed in the systematic literature review on abobotulinumtoxinA onset and duration and consistent with patient education from UTHealth Houston Dermatology. Follow-up visits allow assessment of symmetry and response under normal facial movement. A thoughtful plan grounded in label-supported duration helps patients schedule maintenance without unrealistic promises.

Expectations improve when patients define what “better” means before treatment begins. Some people want a softer, less tense expression, while others want a visible reduction in the depth of the “11” lines during strong frown. Those goals can differ even within the same FDA-indicated area. A clear baseline description, plus an understanding that results remain temporary per the FDA-approved label language, helps avoid the feeling that treatment “stopped working” when the effect naturally fades.

Fountain of Youth in Fort Myers, Florida, stays current on FDA labeling and peer-reviewed developments related to neuromodulator safety and performance so patients receive care aligned with established evidence.

Questions? We are here to help! Call 239-355-3294.

Frequently Asked Questions

How is Dysport different from other botulinum toxin products?

Dysport contains abobotulinumtoxinA and carries its own FDA-approved dosing and clinical data in the FDA-approved prescribing information. The prescribing information states that its units are not interchangeable with those of other botulinum toxin products. Clinical trials for Dysport focused on glabellar lines in adults under 65. Comparisons across brands should rely on published data rather than unit numbers.

When will I start seeing results after Dysport?

Peer-reviewed literature on abobotulinumtoxinA reports that some patients notice effects within 48 to 72 hours, as summarized in a systematic literature review. Improvement often continues over the first week, with clinical endpoints commonly assessed at later follow-up visits such as Day 30. Individual timing varies depending on muscle activity and treatment parameters. Full assessment typically occurs within the first two weeks.

How long does Dysport last for frown lines?

The FDA prescribing information states that Dysport reduces the severity of glabellar lines for up to four months in the FDA-approved label. Dermatology guidance on botulinum toxin therapy broadly describes a duration of about three to four months in the American Academy of Dermatology overview. Some individuals may notice shorter or slightly longer persistence, yet no approved indication supports permanent results. Maintenance planning should reflect this temporary effect.

What symptoms require urgent medical attention?

The boxed warning explains that swallowing, speaking, or breathing difficulties can signal distant spread of toxin effect, as stated in the FDA-approved Dysport label. Such symptoms may occur hours to weeks after injection. Immediate medical evaluation is necessary if breathing or swallowing problems develop. Severe allergic reactions, including anaphylaxis, also require urgent care.

Who should avoid Dysport?

Individuals with hypersensitivity to botulinum toxin products or to components of Dysport should not receive treatment, as listed in contraindications in the FDA-approved label. Infection at the injection site represents another contraindication. Patients with certain neuromuscular disorders face increased risk of swallowing or breathing complications and need individualized assessment. Full disclosure of medical history supports safer care.

Can I receive Dysport if I take other medications?

Aminoglycoside antibiotics and other agents affecting neuromuscular transmission may enhance the effect of Dysport, as described in the drug interactions section of the FDA label. Anticholinergic drugs can increase certain systemic effects when combined. Patients should provide a complete medication list, including recent antibiotics and supplements. Clinicians can then determine whether timing adjustments or precautions are appropriate.

This article reflects information drawn from the current U.S. FDA prescribing information for Dysport, peer-reviewed literature reviewing abobotulinumtoxinA in the upper face, and American Academy of Dermatology patient guidance on botulinum toxin therapy. Mechanism and safety context also draws on the NIH News in Health overview, the CDC MMWR botulism clinical guidelines, UTHealth Houston Dermatology patient education, and the MedlinePlus botulinum toxin overview.

---

Medical review: Reviewed by Dr. Keith Lafferty MD, Fort Myers on March 2, 2026. Fact-checked against government and academic sources; see in-text citations. This page follows our Medical Review & Sourcing Policy and undergoes updates at least every six months.